Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. reported that its VP and Chief Financial Officer, Nicholas B. Hawkins, acquired 41,217 restricted stock units as an equity award. Each RSU represents one share of common stock and vests 1/16 on 4/1/2026, then in equal quarterly installments. Following this grant, he holds 123,484 shares of common stock in total.
Alpern Paul L reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. reported that its VP and General Counsel, Paul L. Alpern, received an equity award of 32,385 restricted stock units (RSUs), each representing one share of common stock, at no cash cost per share. These RSUs will vest as to 1/16 of the total on April 1, 2026, then in equal quarterly installments thereafter, and have no expiration date. Following this grant, Alpern beneficially owns 90,035 shares of common stock, including the 32,385 RSUs.
Arteris, Inc. director and President and CEO K. Charles Janac reported multiple equity movements involving the company’s common stock. On February 18, 2026, he acquired 78,051 shares through a grant of restricted stock units, at a stated price of $0.0000 per share.
According to the footnotes, each RSU represents one share of common stock and will vest as to 1/16 of the total on April 1, 2026, then in equal quarterly installments thereafter, with no expiration date. After this grant, his directly held common stock position was 217,538 shares.
On February 20, 2026, Bayview Legacy, LLC, an entity for which Janac serves as manager with voting and dispositive power, made a bona fide gift of 70,000 common shares at a reported price of $0.0000 per share, leaving 9,279,071 shares indirectly held through that LLC. A separate line item shows 56,252 shares held indirectly by the Charles and Lydia Janac Trust, for which he serves as trustee.
Arteris, Inc. has filed a shelf registration statement covering the resale of up to 985,675 shares of common stock by selling stockholders who received these shares in the Cycuity, Inc. acquisition. The company will not receive any proceeds from these secondary sales.
The selling stockholders may dispose of their shares from time to time using various methods, including brokered and underwritten transactions, as described in the plan of distribution. As context, there were 45,467,261 shares of Arteris common stock outstanding as of February 5, 2026.
Arteris, Inc. has filed a shelf registration statement covering the resale of up to 985,675 shares of common stock by selling stockholders who received these shares in the Cycuity, Inc. acquisition. The company will not receive any proceeds from these secondary sales.
The selling stockholders may dispose of their shares from time to time using various methods, including brokered and underwritten transactions, as described in the plan of distribution. As context, there were 45,467,261 shares of Arteris common stock outstanding as of February 5, 2026.
Arteris, Inc. reports 2025 results showing continued growth but ongoing losses as it invests heavily in semiconductor system IP. Revenue for the year ended December 31, 2025 was $70.6 million, up from $57.7 million in 2024, driven by demand for its network‑on‑chip and SoC integration automation products across automotive, AI, communications, aerospace and other markets.
The company remains unprofitable, with a net loss of $34.7 million in 2025 versus $33.6 million in 2024, reflecting high R&D spending of $49.9 million, or 71% of revenue. Operating cash flow improved to $6.7 million provided in 2025 after using $0.7 million in 2024, signaling better cash discipline despite losses.
Arteris highlights Annual Contract Value of $77.0 million and ACV plus royalties of $83.6 million as of December 31, 2025, indicating a growing recurring revenue base. Management emphasizes leadership in system IP for complex SoCs, expansion into security verification via the Cycuity acquisition, and exposure to fast‑growing AI, automotive and multi‑die chip markets, while warning of intense competition, customer concentration, international and regulatory risks, and the possibility of continued net losses.
Arteris, Inc. reports 2025 results showing continued growth but ongoing losses as it invests heavily in semiconductor system IP. Revenue for the year ended December 31, 2025 was $70.6 million, up from $57.7 million in 2024, driven by demand for its network‑on‑chip and SoC integration automation products across automotive, AI, communications, aerospace and other markets.
The company remains unprofitable, with a net loss of $34.7 million in 2025 versus $33.6 million in 2024, reflecting high R&D spending of $49.9 million, or 71% of revenue. Operating cash flow improved to $6.7 million provided in 2025 after using $0.7 million in 2024, signaling better cash discipline despite losses.
Arteris highlights Annual Contract Value of $77.0 million and ACV plus royalties of $83.6 million as of December 31, 2025, indicating a growing recurring revenue base. Management emphasizes leadership in system IP for complex SoCs, expansion into security verification via the Cycuity acquisition, and exposure to fast‑growing AI, automotive and multi‑die chip markets, while warning of intense competition, customer concentration, international and regulatory risks, and the possibility of continued net losses.
Arteris, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Q4 revenue reached $20.1 million, up 30% year over year, with Annual Contract Value plus royalties at a record $83.6 million, up 28%.
Remaining performance obligations were $116.8 million, up 32%, and Q4 non-GAAP free cash flow was positive $3.0 million. For 2025, revenue was $70.6 million, up 22%, but GAAP net loss was $34.7 million. 2026 guidance calls for revenue of $89.0–$93.0 million and non-GAAP operating loss of $5.0–$9.0 million.
Arteris, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Q4 revenue reached $20.1 million, up 30% year over year, with Annual Contract Value plus royalties at a record $83.6 million, up 28%.
Remaining performance obligations were $116.8 million, up 32%, and Q4 non-GAAP free cash flow was positive $3.0 million. For 2025, revenue was $70.6 million, up 22%, but GAAP net loss was $34.7 million. 2026 guidance calls for revenue of $89.0–$93.0 million and non-GAAP operating loss of $5.0–$9.0 million.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of the company’s common stock under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
The LLC sold 47,244 shares on February 9, 2026 at a weighted average price of $15.2053 per share and 2,756 shares on February 10, 2026 at a weighted average price of $15.0322 per share. After these transactions, it indirectly held 9,349,071 Arteris shares, with voting and dispositive power deemed to be held by manager K. Charles Janac.
Arteris, Inc. reported insider share sales by an entity managed by its President and CEO, Charles K. Janac. Bayview Legacy, LLC, over which he has voting and dispositive power, sold 47,244 shares of common stock on February 9, 2026 at a weighted average price of $15.2053 per share and 2,756 shares on February 10, 2026 at a weighted average price of $15.0322 per share. These sales were made under a Rule 10b5-1 trading plan adopted on March 5, 2025. After these transactions, Bayview Legacy, LLC held 9,349,071 shares indirectly for Janac. He also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported an automatic option exercise and share sale in Arteris, Inc. common stock. On February 2, 2026, he exercised options for 5,000 shares at an exercise price of $0.56 per share and then sold 5,000 shares of common stock at a weighted average price of $15.4753 per share.
The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 5, 2025. Following these transactions, Alpern beneficially owned 57,650 shares of Arteris common stock directly, and 65,000 derivative securities (stock options) remained outstanding with an exercise price of $0.56 per share, expiring on October 23, 2029.
Arteris, Inc. insider activity: An entity associated with President and CEO Charles Janac reported a planned sale of company stock. On January 15, 2026, Bayview Legacy, LLC sold 17,884 shares of Arteris common stock at a weighted average price of $17.8357 per share, under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following this sale, Bayview Legacy, LLC held 9,399,071 shares beneficially owned, over which Janac, as manager, is deemed to have voting and dispositive power.
Separately, Janac held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.